The pharmacist's role in generic substitution

On Aug. 14, 1997, FDA declared that orally administered levothyroxine products were new drugs that would need approved applications to stay on the US market. Since 1991, the agency wrote in the Federal Register⁴, there had been “no less than 10 firm-initiated recalls of levothyroxine sodium tablets involving 150 lots and more than 100 million tablets,” almost all because the pills were subpotent or could not be shown to hold their potency until expiration.

FDA gave makers three years to win approval, later extended to Aug. 14, 2001⁵. Today the thyroid hormone has some of the most complicated equivalence codes in the Orange Book, which makes it a good place to start in explaining what a pharmacist actually checks before handing over a generic.

Substitution looks automatic from the patient's side of the counter. It is a sequence of checks, some set by FDA, some by state law and some by federal Medicaid rules dating to 1990.

Step one is the equivalence code

States generally tie substitution to FDA's therapeutic equivalence ratings, as our companion piece on state generic substitution laws explains. A pharmacist looks up the product in the Orange Book and reads its two-letter code. Codes beginning with A mean FDA considers the product therapeutically equivalent to others under the same heading. Codes beginning with B mean it does not, at least for now.

GxRadar tallied the codes in the Orange Book data files² FDA posted in October 2026. Each row is one strength of one approved, marketed prescription product.

Some codes carry a number. The Orange Book preface¹ says three-character codes such as AB1 and AB2 “generally are assigned only in situations when more than one RLD of the same strength has been designated under the same heading.” (An RLD is the reference listed drug a generic is compared with.) Levothyroxine is the standard example. In the October 2026 files, the tablet heading lists 13 applications, six of them full new drug applications and seven ANDAs. Of its 155 strength listings, 72 carry all four codes, AB1 through AB4. A pharmacist matches the number as well as the letters. Our explainer on therapeutic equivalence codes has the full code list.

Warfarin is simpler on paper. The same files list six ANDAs for warfarin sodium tablets across 54 strength listings, every one coded AB.

Step two is the prescription and the price

Next comes the prescriber's instruction. State laws let a prescriber block substitution, typically with a “dispense as written” instruction. North Carolina's statute⁶, for example, recognizes a signature on a preprinted “Dispense as Written” line, the handwritten phrase, or an oral instruction noted by the pharmacist. The same law bars substitution unless the generic's price to the purchaser is lower than the prescribed product's. FDA's preface¹ leaves room for this kind of judgment, saying that where a product's characteristics other than its active ingredient matter for a particular patient, prescribing that specific product “may be appropriate.”

Narrow therapeutic index drugs get extra rules

Some drugs work in a tight band between too little and too much. A 2015 paper by FDA scientists in Clinical Pharmacology & Therapeutics³ defined narrow therapeutic index (NTI) drugs as those “where small differences in dose or blood concentration may lead to serious therapeutic failures and/or adverse drug reactions.” It proposed tighter bioequivalence limits for them, 90.00 percent to 111.11 percent, scaled to the reference product's variability, in place of the standard limits described in the 80-125 rule.

FDA's equivalence ratings do not carve out NTI drugs. Its preface¹ says products rated therapeutically equivalent “can be substituted with the full expectation” of the same clinical effect and safety profile. Some states add their own layer anyway. North Carolina's G.S. 90-85.28(b1)⁶ requires that a prescription for an NTI drug be refilled with the same manufacturer's product last dispensed, unless the pharmacist notifies the prescriber first and both prescriber and patient give documented consent. The list the state Board of Pharmacy published in January 2003⁷ included levothyroxine tablets, warfarin tablets, carbamazepine, digoxin, lithium, phenytoin, cyclosporine and theophylline.

Price is not the obstacle for these two drugs. In GxRadar's analysis of CMS NADAC data¹⁰, the average pharmacy acquisition cost of a levothyroxine 50 mcg tablet fell from about 22.7 cents in November 2013 to about 4.0 cents in October 2026, a slide traced in levothyroxine and the price of a daily pill. A warfarin 5 mg tablet cost about 8.9 cents in October 2026, slightly more than the 7.5 cents of November 2013.

Step three is the offer to counsel

The counseling duty comes from the Omnibus Budget Reconciliation Act of 1990, Public Law 101-508, signed Nov. 5, 1990, which added the Medicaid drug rebate and drug use review provisions now at 42 U.S.C. 1396r-8⁸. For Medicaid patients, states must run a prospective review before each prescription is filled, screening for therapeutic duplication, drug-disease contraindications, drug interactions, incorrect dosage or duration, drug-allergy interactions and clinical abuse or misuse. The statute also paid states a 75 percent federal match for adopting such programs during 1991 through 1993.

Under the statute, the pharmacist “must offer to discuss” with each Medicaid patient or caregiver matters the pharmacist judges significant, including the name and description of the medication, dosage and duration, side effects and interactions, self-monitoring, storage, refills and what to do about a missed dose. Pharmacists must make a reasonable effort to keep a patient profile. Nothing requires counseling when the patient refuses it.

CMS's implementing rule at 42 CFR 456.705⁹, first published in November 1992, leaves the details to each state: whether the offer applies to refills as well as new prescriptions, whether staff other than the pharmacist may make the offer, and what must be documented. Mail-order pharmacies must provide toll-free telephone access for long-distance calls. A pill that changes shape or color at refill, a common sign of a manufacturer switch, is covered in why your pill changed color, and our pharmacist script lists questions patients often bring to that conversation.

Equivalence codes, the first check in this sequence, also move. The Hatch-Waxman Amendments¹ require FDA to publish the list with monthly supplements, so a product's rating, or the set of products it is rated against, can change between one refill and the next.